# A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

> **NCT07100210** · PHASE1 · RECRUITING · sponsor: **Xingchen Peng** · enrollment: 6 (estimated)

## Conditions studied

- Refractory Malignant Solid Tumors
- mRNA Vaccine
- Interleukin

## Interventions

- **BIOLOGICAL:** IL-22BP mRNA vaccine injection

## Key facts

- **NCT ID:** NCT07100210
- **Lead sponsor:** Xingchen Peng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-02-20
- **Final completion:** 2026-02-20
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100210, "A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07100210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*